Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 证券代码：688089 证券简称：嘉必优 公告编号：2025-056 嘉必优生物技术（武汉）股份有限公司 关于 2025 年半年度业绩预增的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 经财务部门初步测算： 1、2025 年半年度实现营业收入约 30,670 万元，较上年同期增长 17.59%； 2、2025 年半年度实现归属于母公司所有者的净利润约 10,700 万元，较上年 同期增长 57.61%； 3、2025 年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约 9,300 万元，较上年同期增长 75.45%。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 1、2024 年半年度营业收入：26,083.24 万元； 2、2024 年半年度利润总额：7,803.82 万元； 四、风险提示 公司本次业绩预告数据未经注册会计师审计，为 ...

Core Viewpoint - The company reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and growth in key product sales [1] Financial Performance - The company achieved a revenue of approximately 307 million yuan, representing a year-on-year growth of 17.59% [1] - The net profit attributable to the parent company was around 107 million yuan, reflecting a year-on-year increase of 57.61% [1] - The net profit excluding non-recurring gains and losses was approximately 93 million yuan, which is a 75.45% increase compared to the same period last year [1] Operational Drivers - The increase in revenue was primarily driven by higher sales volumes of core products ARA and algal oil DHA [1] - Profit growth was attributed to the rise in revenue, improved production efficiency, and optimization of product and customer structures, enhancing the company's profitability [1]

Core Viewpoint - The article discusses the emerging significance of Extracellular Matrix (ECM) in anti-aging skincare, highlighting the potential of N-acetylneuraminic acid (also known as "Nectar Acid") as a key ingredient in this new approach to skincare [2][3][15]. Group 1: ECM and Anti-Aging - ECM has been identified as the thirteenth hallmark of aging, representing a new pathway for anti-aging technology in the beauty industry [2][8]. - Major beauty companies like L'Oréal, Estée Lauder, Shiseido, and others are actively investing in ECM-related research and development, indicating a competitive landscape [8][11]. Group 2: N-acetylneuraminic Acid (Nectar Acid) - N-acetylneuraminic acid has recently been approved by the National Medical Products Administration in China, marking its transition from experimental to a recognized cosmetic ingredient [3][15]. - This ingredient exhibits multiple biological activities, including anti-wrinkle, brightening, anti-inflammatory properties, and the ability to regulate ECM homeostasis [15][22]. Group 3: Mechanisms and Efficacy - N-acetylneuraminic acid significantly enhances collagen gene promoter activity, leading to a 252% increase in type I collagen synthesis at a concentration of 0.2% [18]. - It acts as a stabilizer for ECM by neutralizing reactive oxygen species (ROS) and inhibiting matrix metalloproteinases (MMP-1, MMP-3, MMP-9), thereby reducing collagen degradation [20][22]. Group 4: Market Potential and Applications - The successful incorporation of N-acetylneuraminic acid into the cosmetic ingredient directory opens up new market opportunities and enhances its commercial value [26][27]. - The ingredient's dual application in both topical and oral beauty products aligns with traditional Asian wellness practices, providing a strong foundation for cross-category integration [26][28]. Group 5: Research and Development - The company has invested over 30 million yuan in the industrialization of N-acetylneuraminic acid, overcoming traditional extraction challenges to achieve high purity and yield [28][29]. - Ongoing research focuses on multi-omics studies to validate the ingredient's efficacy across various biological pathways, enhancing its appeal in the anti-aging market [25][34].

嘉必优生物技术（武汉）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688089 证券简称：嘉必优 公告编号：2025-055 ? 股东持股的基本情况 截止本公告披露日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）股东马涛先生持有公司股份 157,373 股，占公司总股本的 0.0935%。其中 易买入股份，34,392 股来源于公司 2022 年度资本公积转增股本，均为无限售流 通股。 ? 减持计划的主要内容 马涛先生因个人资金需求，拟于减持计划披露之日起 15 个交易日后的 3 个 月内通过集中竞价方式减持其所持有的公司股份，合计数量不超过 150,000 股， 即不超过公司总股本的 0.0891%。 ? 特别说明 马涛先生系原公司第三届高级管理人员，现已卸任高级管理人员职位届满 6 个月，按照现行法律法规要求无需披露减持计划，但因公司拟并购上海欧易生物 医学科技有限公司 63.2134%股权项目签署了承诺函："自本次交易复牌之日起 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-055 嘉必优生物技术（武汉）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截止本公告披露日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）股东马涛先生持有公司股份 157,373 股，占公司总股本的 0.0935%。其中 85,981 股来源于公司首次公开发行前取得，37,000 股来源于二级市场集中竞价交 易买入股份，34,392 股来源于公司 2022 年度资本公积转增股本，均为无限售流 通股。 上述减持主体无一致行动人。 二、减持计划的主要内容 | 股东名称 | 马涛 | | | | | | --- | --- | --- | --- | --- | --- | | 计划减持数量 | 不超过：150,000 股 | | | | | | 计划减持比例 | 不超过：0.0891% | | | | | | 减持方式及对应减持数 量 | 股 集中竞价减持，不超过：15 ...

嘉必优公告，股东马涛因个人资金需求，计划于2025年7月29日至2025年10月28日期间，通过集中竞价 方式减持不超过15万股，占公司总股本的0.0891%。马涛先生目前持有公司股份15.74万股，占公司总股 本的0.0935%。 ...

Group 1 - The stock price of Jia Bi You (688089) closed at 25.13 yuan on July 4, 2025, up 0.44% from the previous week [1] - The company's market capitalization is currently 4.23 billion yuan, ranking 93rd out of 169 in the chemical products sector and 3463rd out of 5149 in the A-share market [1] - The company announced a cash dividend of 0.20094 yuan per share, with the record date on July 9, 2025, and the payment date on July 10, 2025, totaling approximately 33.66 million yuan distributed among 167,519,992 shares [1] Group 2 - The company adjusted the upper limit for the second phase of share repurchase from 25.00 yuan to 24.80 yuan per share, effective from July 10, 2025 [2] - As of June 30, 2025, the company has not yet repurchased any shares through its dedicated securities account, with the repurchase plan initially disclosed on January 25, 2025, and an expected amount between 15 million and 30 million yuan [2][3]

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan, proposing a cash dividend of 0.20094 yuan per share, which was approved at the 2024 annual shareholders' meeting on May 29, 2025 [1][2][3]. Dividend Distribution Plan - The cash dividend of 0.20094 yuan per share is inclusive of tax, and the total number of shares eligible for distribution is 167,519,992 after deducting 789,128 shares held in the company's repurchase account from the total share capital of 168,309,120 shares [2][3]. - The company will not issue bonus shares or increase capital reserves, and the remaining undistributed profits will be carried forward to future years [2][3]. Ex-Dividend Date and Payment Date - The relevant dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [3]. Taxation on Dividends - For individual shareholders and securities investment funds, the cash dividend of 0.20094 yuan per share will not be subject to withholding personal income tax at the time of distribution. Tax will be calculated based on the holding period when the shares are sold [5][6]. - For qualified foreign institutional investors (QFIIs), a 10% corporate income tax will be withheld, resulting in an actual cash dividend of 0.18085 yuan per share [6]. - Hong Kong investors will also have a 10% withholding tax applied, with the same actual cash dividend of 0.18085 yuan per share, and they may apply for tax treaty benefits if applicable [6]. Implementation of Dividend Distribution - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders who have registered their shares by the record date [3][7]. - Shares held in the company's repurchase account will not participate in the profit distribution [3].

Core Viewpoint - The legal opinion issued by Beijing Zhonglun Law Firm confirms that the differentiated dividend distribution plan proposed by Jia Biyou Biotechnology (Wuhan) Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6][11][12]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.20094 RMB per share, totaling approximately 33.66 million RMB, calculated on a base of 167,519,992 shares after deducting repurchased shares [9][10]. - The company has repurchased 789,128 shares, and the total share capital is 168,309,120 shares, which affects the calculation of the dividend distribution [10][11]. - The company will not conduct capital reserve transfers or issue bonus shares, with any remaining undistributed profits carried forward to future years [11]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and facts provided by the company, ensuring the accuracy and completeness of the legal opinion [4][5]. - The legal opinion is based on existing laws, regulations, and the company's articles of association, confirming that the differentiated dividend distribution does not violate any legal provisions [6][12]. - The law firm emphasizes that the opinion is solely for the purpose of the differentiated dividend distribution and cannot be used for any other purpose without consent [5][12].